Hansa Biopharma AB Share Price Mexican S.E.
Equities
HNSA N
SE0002148817
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
160.8 MXN | -.--% | -.--% | -.--% |
21/05 | Hansa Biopharma to Present Data At 2024 American Transplant Congress Annual Meeting | CI |
18/04 | Transcript : Hansa Biopharma AB, Q1 2024 Earnings Call, Apr 18, 2024 |
Sales 2024 * | 239M 22.42M 380M 1.87B | Sales 2025 * | 343M 32.11M 544M 2.67B | Capitalization | 2.7B 253M 4.28B 21.04B |
---|---|---|---|---|---|
Net income 2024 * | -735M -68.87M -1.17B -5.74B | Net income 2025 * | -712M -66.72M -1.13B -5.56B | EV / Sales 2024 * | 13.2 x |
Net Debt 2024 * | 474M 44.42M 752M 3.7B | Net Debt 2025 * | 733M 68.72M 1.16B 5.72B | EV / Sales 2025 * | 10 x |
P/E ratio 2024 * |
-3.65
x | P/E ratio 2025 * |
-4.33
x | Employees | 166 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.64% |
Latest transcript on Hansa Biopharma AB
Managers | Title | Age | Since |
---|---|---|---|
Søren Tulstrup
CEO | Chief Executive Officer | 59 | 20/18/20 |
Hitto Kaufmann
CTO | Chief Tech/Sci/R&D Officer | 53 | 01/12 |
Achim Kaufhold
CTO | Chief Tech/Sci/R&D Officer | 66 | 29/20/29 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 73 | 29/18/29 | |
Peter Nicklin
CHM | Chairman | 61 | 30/22/30 |
Mats Blom
BRD | Director/Board Member | 59 | 22/19/22 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+49.24% | 58.71B | |
-2.87% | 41.31B | |
+36.42% | 39.2B | |
-11.22% | 27.4B | |
+9.64% | 26.55B | |
-22.73% | 18.98B | |
+1.95% | 12.51B | |
+26.32% | 12.08B | |
+22.14% | 11.94B |
- Stock Market
- Equities
- HNSA Stock
- HNSA N Stock